HTG Molecular Diagnostics, Inc. (HTGM) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

HTG Molecular Diagnostics, Inc. (HTGM) Healthcare & Pipeline Overview

HTG Molecular Diagnostics, Inc. offers molecular profiling solutions for precision medicine, including instruments, consumables, and software. Their HTG EdgeSeq technology serves biopharmaceutical companies and research institutions by automating sample processing and profiling molecular targets. The company distributes its products in the United States, Europe, and internationally.

What Is the Investment Thesis for HTGM?

HTG Molecular Diagnostics, Inc. operates in the growing precision medicine market, offering potential for revenue expansion through its HTG EdgeSeq technology. Key value drivers include increasing adoption of molecular profiling in oncology and drug development. Growth catalysts include expansion of the product portfolio with new assays and panels. However, the company's negative profit margin of -339.2% and small market capitalization of $1.06M present significant financial risks. Investors should closely monitor HTG's ability to achieve profitability and secure additional funding to sustain operations. The company's beta of 0.99 indicates market correlation.

Based on FMP financials and quantitative analysis

HTGM Key Highlights

• HTG Molecular Diagnostics operates in the precision medicine sector, which is experiencing growth due to advancements in genomics and personalized healthcare.
• The company's HTG EdgeSeq technology offers a differentiated approach to molecular profiling, potentially capturing market share from traditional methods.
• HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, providing a diversified customer base.
• The company's gross margin of 28.2% indicates potential for profitability improvements through economies of scale and product mix optimization.
• HTG's distribution network covers the United States, Europe, and international markets, providing a global reach for its products.

Who Are HTGM's Competitors?

HTGM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HTGM's Key Strengths?

• Proprietary HTG EdgeSeq technology platform.
• Established relationships with key customers in the biopharmaceutical and academic sectors.
• Growing portfolio of molecular profiling assays and panels.
• Distribution network covering key global markets.

What Are HTGM's Weaknesses?

• Negative profit margin and reliance on external funding.
• Small market capitalization and limited financial resources.
• Intense competition in the molecular diagnostics market.
• Dependence on a limited number of key products and customers.

What Could Drive HTGM Stock Higher?

• Potential FDA approval of new HTG EdgeSeq assays, expanding clinical utility.
• Expansion of strategic partnerships with biopharmaceutical companies for companion diagnostics development.
• Increasing adoption of HTG EdgeSeq technology in academic research centers and molecular testing laboratories.
• Publication of clinical studies demonstrating the value of HTG EdgeSeq assays in personalized medicine.

What Are the Key Risks for HTGM?

• Financial-distress signal — its Altman Z-Score of -35.26 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to achieve profitability and reliance on external funding.
• Intense competition in the molecular diagnostics market.
• Technological obsolescence and the emergence of competing technologies.
• Regulatory changes and reimbursement pressures.
• Economic downturns and reduced healthcare spending.

What Are the Growth Opportunities for HTGM?

• Expansion of HTG EdgeSeq Menu: HTG can expand its portfolio of HTG EdgeSeq assays and panels to address new therapeutic areas and disease indications. This includes developing assays for liquid biopsy, infectious diseases, and other emerging areas of interest. Timeline: Ongoing.
• Strategic Partnerships with Biopharmaceutical Companies: HTG can forge strategic partnerships with biopharmaceutical companies to co-develop and commercialize companion diagnostics. These partnerships can provide HTG with access to new markets, funding, and expertise. The market for companion diagnostics is growing rapidly, driven by the increasing demand for personalized medicine. Timeline: Ongoing.
• Geographic Expansion into Emerging Markets: HTG can expand its geographic presence into emerging markets, such as Asia-Pacific and Latin America, where the demand for molecular diagnostics is growing rapidly. This expansion can be achieved through strategic partnerships with local distributors and collaborators. The market for molecular diagnostics in emerging markets is expected to grow at a faster pace than in developed markets. Timeline: 2027-2029.
• Development of Integrated Diagnostic Solutions: HTG can develop integrated diagnostic solutions that combine its HTG EdgeSeq technology with other diagnostic modalities, such as imaging and clinical data. This integration can provide clinicians with a more comprehensive view of the patient's condition, leading to more informed treatment decisions. The market for integrated diagnostic solutions is growing, driven by the increasing demand for personalized medicine. Timeline: 2028-2030.
• Leveraging AI and Machine Learning: HTG can leverage artificial intelligence (AI) and machine learning (ML) to enhance its HTG EdgeSeq technology and develop new diagnostic applications. AI and ML can be used to analyze large datasets of molecular profiling data, identify biomarkers, and predict patient outcomes. The market for AI-powered diagnostics is growing rapidly, driven by the increasing availability of data and the advancements in AI and ML technologies. Timeline: Ongoing.

What Opportunities Does HTGM Have?

• Expansion of HTG EdgeSeq menu to address new therapeutic areas.
• Strategic partnerships with biopharmaceutical companies for companion diagnostics.
• Geographic expansion into emerging markets.
• Development of integrated diagnostic solutions.

What Threats Does HTGM Face?

• Technological obsolescence and the emergence of competing technologies.
• Regulatory changes and reimbursement pressures.
• Economic downturns and reduced healthcare spending.
• Intellectual property infringement and patent challenges.

What Are HTGM's Competitive Advantages?

• Proprietary HTG EdgeSeq technology platform.
• Established relationships with biopharmaceutical companies and academic research centers.
• Growing portfolio of HTG EdgeSeq assays and panels.
• Distribution network covering the United States, Europe, and international markets.

What Does HTGM Do?

HTG Molecular Diagnostics, Inc., founded in 1997 and based in Tucson, Arizona, is a life sciences company dedicated to advancing precision medicine through molecular profiling. Originally incorporated as HTG, Inc., the company rebranded to HTG Molecular Diagnostics, Inc. in March 2011 to better reflect its focus. HTG develops, manufactures, and markets instruments, consumables (assay kits), and software designed to automate sample processing and profile various molecular targets. These products enable researchers and clinicians to gain deeper insights into disease mechanisms and develop more effective therapies. The company's key offerings include the HTG Transcriptome Panel and the HTG EdgeSeq product line, which encompasses a range of molecular profiling panels such as the HTG EdgeSeq precision immuno-oncology panel, miRNA whole-transcriptome assay, DLBCL cell of origin assay, Oncology Biomarker Panel, ALKPlus assay, and Pan B-Cell Lymphoma Panel. These panels are designed to analyze specific sets of genes or RNA molecules, providing valuable information for cancer research, drug development, and diagnostic applications. HTG distributes its products directly in the United States and Europe, and through distributors in other parts of Europe and internationally. The company serves a diverse customer base, including biopharmaceutical companies, academic research centers, and molecular testing laboratories, and has a governing agreement with QIAGEN Manchester Limited.

What Products and Services Does HTGM Offer?

• Develop and market instruments for molecular profiling.
• Offer consumables, including assay kits, for use with their instruments.
• Provide software solutions for automating sample processing and data analysis.
• Offer the HTG Transcriptome Panel for comprehensive gene expression analysis.
• Offer HTG EdgeSeq panels for various applications, including immuno-oncology and lymphoma diagnostics.
• Distribute their products directly in the United States and Europe.
• Distribute their products through distributors in other parts of Europe and internationally.
• Serve biopharmaceutical companies, academic research centers, and molecular testing laboratories.

How Does HTGM Make Money?

• Sale of instruments for molecular profiling.
• Recurring revenue from the sale of consumables (assay kits).
• Software licensing and service agreements.
• Strategic partnerships with biopharmaceutical companies for co-development and commercialization.

What Industry Does HTGM Operate In?

HTG Molecular Diagnostics operates within the medical diagnostics and research industry, a segment driven by advancements in genomics, proteomics, and personalized medicine. The market is characterized by intense competition among established players and emerging companies offering innovative diagnostic solutions. Key trends include the increasing adoption of molecular profiling in oncology, drug development, and personalized healthcare. HTG competes with companies like ACOR, AXDX, CWBR, CYTO, and IMPL, focusing on specific niches within the broader diagnostics market. The industry is expected to continue growing, driven by the increasing demand for more precise and personalized diagnostic tools.

Who Are HTGM's Key Customers?

• Biopharmaceutical companies involved in drug discovery and development.
• Academic research centers conducting basic and translational research.
• Molecular testing laboratories providing diagnostic services to clinicians.

HTG Molecular Diagnostics, Inc. (HTGM) Valuation Context

Valued at $1.06M, HTGM is classified as a micro-cap stock. Relative to its peer group, HTGM's quantitative score of 46/100 is roughly in line with the peer average of 54/100.

F-Score 3/9Financial Health

HTG Molecular Diagnostics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.26 places it in the distress zone, a signal of elevated financial risk.

Net buyingInsider Activity

The most recent 12 insider filings for HTG Molecular Diagnostics, Inc. break down as 5 sales and 7 purchases. On net that is roughly 9K shares acquired (about $272K) — insiders putting money in tends to read as conviction.

HTGM Financials

HTGM Latest News

No recent news available for HTGM.

HTGM Analyst Consensus

HTGM MoonshotScore

Common Questions About HTGM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources